Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis
申请人:Hentemann Martin
公开号:US20110083984A1
公开(公告)日:2011-04-14
This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
该发明涉及一种新型的2,3-二氢咪唑[1,2-c]喹唑啉化合物,以及含有这些化合物的药物组合物,以及用于磷脂酰肌醇-3-激酶(PI3K)抑制和治疗与磷脂酰肌醇-3-激酶(PI3K)活性相关的疾病的这些化合物或组合物的用途,特别是作为单独的药物或与其他活性成分联合使用,用于治疗过度增殖和/或血管生成异常。